BusinessSummit Enters Into Licence and Commercialisation Agreement With Eurofarma for Latin American Rights to Ridinilazole, Summit’s Precision Antibiotic in Development for the Treatment of CDIBy Nasdaq OMXDec 21, 2017, 7:00 AM UTC
BusinessSummit Therapeutics to Participate in Upcoming Investor ConferencesBy Nasdaq OMXNov 22, 2017, 12:00 PM UTC
BusinessSummit Announces Signing of Revenue Sharing Agreement With the Wellcome Trust for CDI Antibiotic RidinilazoleBy Nasdaq OMXNov 6, 2017, 2:29 PM UTC
BusinessSummit Highlights Microbiome Preservation During Ridinilazole Treatment in Exploratory Phase 2 Clinical Trial at ID Week 2017By Nasdaq OMXOct 9, 2017, 11:00 AM UTC
BusinessSummit Awarded BARDA Contract Worth Up to $62 Million to Support the Development of Ridinilazole for the Treatment of C. difficile InfectionBy Nasdaq OMXSep 11, 2017, 11:00 AM UTC
BusinessSummit Announces Positive Top-Line Data From an Exploratory Phase 2 Clinical Trial Supporting Ridinilazole as a Highly Selective Antibiotic for the Treatment of CDIBy Nasdaq OMXSep 5, 2017, 11:01 AM UTC
BusinessSummit Therapeutics Reports Financial Results for the Second Quarter and Half Year Ended 31 July 2017 and Operational ProgressBy Nasdaq OMXAug 31, 2017, 11:00 AM UTC
